Home Medilink Therapeutics Announces B7-H3 ADC Achieves Primary Endpoint in Nasopharyngeal Carcinoma Phase III Study

Medilink Therapeutics Announces B7-H3 ADC Achieves Primary Endpoint in Nasopharyngeal Carcinoma Phase III Study

May 23, 2026 19:00 CST Updated 19:10